MedTrace Logo

Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain

NCT06848348 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2026-05-29

No results posted yet for this study

Summary

A randomized study to determine safety and efficacy of a series of subcutaneous (SC) injections of HAL in patients with CINP, compared to matching placebo injections. After that, subjects may have the option to enter an Open Label extension phase, where available, in which all subjects will receive Halneuron.

Conditions

  • Chemotherapy Induced Neuropathic Pain
  • Chemotherapy Induced Pain Neuropathy
  • Chemotherapy Induced Pain

Interventions

DRUG

Placebo

Placebo for Subcutaneous Injection

DRUG

Halneuron (Open Label Extension)

Halneuron for Subcutaneous Injection

DRUG

Halneuron

Halneuron for Subcutaneous Injection

Sponsors & Collaborators

  • Dogwood Therapeutics Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-21
Primary Completion
2026-07-31
Completion
2026-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06848348 on ClinicalTrials.gov